

## REMARKS

Claims 7-9 and 12 have been amended and claims 15-18 have been added to more particularly define the scope of the subject matter to be claimed. Support for the amended and added claims appears throughout the specification as filed, e.g., original claims 7-9 and 12. No new matter is added by these amendments, and their entry is respectfully requested.

Applicants acknowledge with appreciation the courtesies extended by Examiner Ha during the telephone conversation with the undersigned on July 16, 2009. No exhibits or art were shown or discussed and no agreement was reached.

This paper is filed in response to the Office Action mailed June 17, 2009 that made restriction and election of species requirements. Applicants were requested to elect one of five (5) designated groups and elect a species.

In response to these requirements, Applicants hereby elect with traverse Group 2, and the species of the polypeptide having an insertion of DPAGF between amino acids corresponding to amino acids 196 and 197 and substitution V16A of SEQ ID NO: 6. Claims 6, 8, 10, 12, 15-17 read on the elected species. Applicants hereby reserve the right to file divisional applications directed to the nonelected subject matter.

Applicant respectfully traverses this requirement. The basis for traverse is that there would not be a serious burden on the examiner if restriction were not required. Moreover, the above-captioned application was entered into the national stage under 35 U.S.C. 371, i.e. filed via the PCT. Significantly, no objection to unity of invention was raised at any point of the PCT phase. Applicant respectfully requests reconsideration and withdrawal of the restriction requirement.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

All required fees were charged to Novozymes North America, Inc.'s Deposit Account No. 50-1701 at the time of electronic filing. The USPTO is authorized to charge this Deposit Account should any additional fees be due.

Respectfully submitted,

Date: July 17, 2009

/Kristin McNamara, Reg. # 47692/  
Kristin J. McNamara, Reg. No. 47,692  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097